Intuitive Surgical: One press release; so much innovation

Research evidence excerpt

Intuitive Surgical: One press release; so much innovation

Accessible version

Intuitive Surgical

One press release; so much innovation

Maintain Rating: BUY | PO: 520.00 USD | Price: 439.80 USD

More innovation here than we can fully appreciate 21 May 2026

ISRG’s press release today highlighted recent innovation across the portfolio. It is clear Equity

dV5 is not sitting still (100 updates and user experience improvements that will soon be

Travis Steed

available to all dV5 users). The release also highlighted advancing augmented dexterity Research Analyst

and automated instrument control which could mean this is getting closer (we’ve been BofAS +1 404 607 3251

talking about this since our Oct 2024 note). We think there’s more innovation and travis.steed@bofa.com

advancements in this press release than we can fully appreciate. But here we wanted to Stephanie Elghazi

spend some time on the new extended use instrument announcement in the release. Research Analyst BofAS

New extended use program for core instruments stephanie.elghazi@bofa.comGracia Mahoney

ISRG said in 2027 it anticipates the number of uses on certain core instruments will Research Analyst

BofAS

again increase, reducing per-procedure costs for da Vinci surgery. ISRG is not yet saying gracia.mahoney@bofa.com

what the impact is on 2027 (likely get more info as 2026 progresses). ISRG is also not Enjia Cao

saying which instruments or how many uses are being extended. When ISRG brings Research Analyst

innovation and value to the market it will capture some of that value. But ISRG also has enjia.cao@bofa.com

been working hard to reduce costs to generate savings it can share with customers. Aidan Lahey

Research Analyst

BofASThe last extended use program was Oct 2020 aidan.lahey@bofa.com